SENSEX NIFTY

Novo Nordisk

Sep 29, 2016 at 13:40 | Source: PTI
"This is one of several actions taken to reduce operating costs as the company faces a challenging competitive environment in 2017, especially in its large US market," the Denmark-based company said in a statement.
Apr 26, 2016 at 18:54 | Source: PTI
Haemophilia is a chronic, inherited bleeding disorder that primarily affects males. People with haemophilia A are either missing or have a malfunctioning factor VIII protein, which is essential for proper blood clotting.
Jul 17, 2015 at 09:49 | Source: Moneycontrol.com
The pharma major has received an approval from the USFDA for PrandiMet (also known as Prandin) generic that is used for treatment of type 2 diabetes.
Oct 09, 2013 at 13:00 | Source: Reuters
The concept of oral insulin as a way to relieve people with type 1 diabetes of several daily injections has been around since the 1930s.
Sep 03, 2013 at 21:14 | Source: CNBC-TV18
Danish drug maker Novo Nordisk is all set to launch its ultra long-lasting insulin injection, brand named Tresiba, in India by the end of this year.
Feb 14, 2013 at 10:18 | Source: Moneycontrol.com
Biocon shares rose 2 percent in morning trade on Thursday after the biotechnology company said it has enhanced its partnership with pharma major Mylan through a strategic collaboration for insulin products.
Apr 18, 2012 at 14:20 | Source: Moneycontrol.com
Shares of pharma major Sun Pharmaceutical Industries rose over 2.5% on Wednesday, after US Supreme Court gave a verdict in favour of its arm Caraco Pharmaceutical Laboratories in the ongoing battle with Novo Nordisk for a generic version of diabetic drug Prandin.
Apr 17, 2012 at 20:36 | Source: Reuters
The US Supreme Court ruled on Tuesday in favor of a generic drugmaker in a case over how companies can fight brand-name rivals in an effort to get their cheaper medicines to market.
Apr 16, 2012 at 18:54 | Source: CNBC-TV18
Novo Nordisk, in association with CNBC-TV18, presents "Improving Control of Diabetes Pandemic in India". In this discussion, experts address the challenges and management of diabetes in India.
Mar 20, 2012 at 21:43 | Source: CNBC-TV18
Multi-national drug companies are queuing up to enter India and tap its growing anti-diabetes drug market. But Novo Nordisk, which has been in the Indian insulin market for 75 years, is not worried, reports CNBC-TV18's Archana Shukla.
Messages on Novo Nordisk »

Willwin

Platinum Member

1077 Followers

Biocon  

The world`s largest insulin maker Novo Nordisk (NOVOb.CO) slashed its long-term growth forecast on Friday, signaling no let-up in its struggles to crack the key U.S. market and sending its shares into a tailspin. See Reuters news.

5.51 PM Oct 28th

biomagic

New Member

13 Followers

Biocon  

Diabetes has emerged as the leading non-communicable disease in India. The market for insulins constitute a little less than a fourth of the overall anti-diabetes market – this is where Biocon sees a huge potential – but it faces stiff competition from Denmark-based Novo Nordisk A/S, US-based Eli

2.22 PM Oct 7th

koppik

Gold Member

12 Followers

Biocon  

Novo Nordisk Plans to Cut 1,000 Jobs Amid Diabetes Price War "Novo is reviewing whether oral insulin can be commercially viable, and how much investment would be needed, Mads Krogsgaard Thomsen, the chief science officer, said in an interview earlier this month. The drugmaker has shifted its focus

4.55 PM Sep 29th

Wire News

Platinum Member

673 Followers

News Now  

Copenhagen, Sep 29 (AFP) The world's largest maker of diabetes treatments, Novo Nordisk, said today it was cutting 1,000 jobs worldwide to cut costs as it faces price pressure in the United States.

1.40 PM Sep 29th

Web Messenger

Platinum Member

369278 Followers

News Now  

Source:Business Week - European stocks rose after a report said Spain will next week unveil an economic reform program that will allow the indebted country to seek a bailout. U.S. index futures and Asian shares also advanced. Novo Nordisk A/S (NOVOB) climbed 1.1 percent

2.07 PM Sep 22nd 2012

Web Messenger

Platinum Member

369278 Followers

News Now  

Source:Market Watch - MADRID (MarketWatch) — European stock markets wobbled on the edge of a fifth consecutive day of gains on Thursday, with some slim lines of support from Chinese economic data and well-received results from heavyweights Novo Nordisk AS and Nestlé SA. The Stoxx Europe 600 index

11.13 AM Aug 10th 2012

Web Messenger

Platinum Member

369278 Followers

News Now  

Source:Business Week - By Albertina Torsoli on June 09, 2012 An experimental insulin from Novo Nordisk A/S (NOVOB) reduced the rate of dangerously low night-time blood sugar levels more than Sanofi (SAN)'s Lantus, a late-stage study showed. The product, degludec, lowered

11.44 AM Jun 11th 2012

Web Messenger

Platinum Member

369278 Followers

News Now  

Source:Bloomberg - An experimental insulin from Novo Nordisk A/S (NOVOB) reduced the rate of dangerously low night-time blood sugar levels more than Sanofi (SAN)'s Lantus, a late-stage study showed. The product, degludec, lowered nocturnal hypoglycemia by 36 percent

11.41 AM Jun 11th 2012

Web Messenger

Platinum Member

369278 Followers

News Now  

Source:Bloomberg - Novo Nordisk A/S (NOVOB) said patients taking its Victoza diabetes drug had greater weight loss than those using Amylin Pharmaceuticals Inc. (AMLN)'s Byetta or a class of drug known as DPP-4 inhibitors. Novo is presenting the data at the American

10.18 AM Jun 11th 2012

Web Messenger

Platinum Member

369278 Followers

News Now  

Source:Business Week - By Phil Serafino on June 10, 2012 Novo Nordisk A/S (NOVOB) said patients taking its Victoza diabetes drug had greater weight loss than those using Amylin Pharmaceuticals Inc. (AMLN) (AMLN)'s Byetta or a class of drug known as DPP-4 inhibitors.

10.02 AM Jun 11th 2012

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.